NL-OMON32654已完成2 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATE
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •18 - 70 years of age
- •Polycystic liver disease (PCLD), defined as >= 20 liver cysts and total liver volume must be at least 2500 mL.
- •Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.
排除标准
- •- Use of estrogens
- •- Pregnancy or breastfeeding at baseline/during study
- •- Severe cardiac or pulmonary disease
- •- Intervention < 3 months before baseline
- •- Kidney transplantation
- •- Symptomatic gallstones
- •- Untreated hypercholesterolemie (fasting cholesterol > 8 mmol/L)
- •- Granulocytopenia (white blood cell < 3,000/mm3) or thrombocytopenia (platelets < 100,000/mm3)
- •- Infection with hepatitis B, hepatitis C, HIV or TBC
- •- Mental illness that interferes with ability to comply with study protocol
- •- Drug or alcohol abuse within one year before baseline
- •- Co-medication that interferes with study medication
- •- Hypersensitivity to everolimus or octreotide
研究者
相似试验
进行中（未招募）
1 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATEIsolated polycystic liver diseaseMedDRA version: 12.1Level: LLTClassification code 10048834Term: Polycystic liver diseaseMedDRA version: 12.1Level: PTClassification code 10048834Term: Polycystic liver diseaseEUCTR2009-016640-39-NLRadboud University Nijmegen Medical Centre44
进行中（未招募）
1 期
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
进行中（未招募）
1 期
Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer - RAD001 and carboplatin in pretreated metastatic breast cancerEUCTR2008-006055-52-DECharité - University Hospital of Berlin58
招募中
4 期
Investigating the occurrence of everolimus long-term side effects by follow up of everolimus trough blood concentrations.Breast cancerNL-OMON50487Medisch Universitair Ziekenhuis Maastricht40
已完成
2 期
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NETGastrointestinal NeoplasmsNCT01567488Grupo Espanol de Tumores Neuroendocrinos43